SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2018
PRESSURE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
or other jurisdiction
14 Norfolk Avenue
South Easton, Massachusetts 02375
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (508) 230-1828
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|[ ]||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|[ ]||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|[ ]||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|[ ]||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 7.01 Regulation FD Disclosure.
On November 14, 2018, an interview with Richard T. Schumacher, the Chief Executive Officer and President of Pressure BioSciences, Inc. (the “Company”) was posted to the website of Uptick Newswire and released to the public by a press release in the U.S. and Canada. In this interview, Mr. Schumacher disclosed that the Company believes that utilizing its technology platform of combining ultra-high pressure and shearing (which the Company calls Ultra Shear Technology), Cannabidiol (“CBD”) plant oil can be made water soluble. In addition, on the same day, Mr. Schumacher conducted the Company’s regular quarterly financial results and business update conference call. On that call, Mr. Schumacher disclosed that the Company had used its Ultra Shear Technology to make CBD plant oil water soluble. On that call, Mr. Schumacher further disclosed that on November 15, 2018, the Company would issue a press release on that achievement, which is expected to have an embedded link to a video describing the Ultra Shear Technology process and showing it make CBD plant oil water soluble.
The information provided in this Item 7.01 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference to such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
|PRESSURE BIOSCIENCES, INC.|
|Dated: November 14, 2018||By:||/s/ Richard T. Schumacher|
|Richard T. Schumacher|